Sign in

    Jeff

    Senior Equity Research Analyst at B. Riley

    Jeff Van Sinderen is a Senior Equity Research Analyst at B. Riley Securities, specializing in consumer products, specialty retail, and a range of consumer-facing industries. He covers companies such as Tilly’s, Celsius Holdings, Herbalife Nutrition, Modine Manufacturing, Universal Electronics, VSE Corp., XPEL, and Zumiez, with a track record that includes a 52% profitability rate on published recommendations and a 29.60% average return per transaction according to TipRanks. Van Sinderen has been with B. Riley since 1997, following prior experience at Imperial Capital, and has received recognition from the Wall Street Journal, Financial Times, and TipRanks as a top-performing analyst. He holds a B.A. from Pepperdine University focused on business and organizational communication, and possesses over 30 years’ experience in equity research.

    Jeff's questions to CytomX Therapeutics (CTMX) leadership

    Jeff's questions to CytomX Therapeutics (CTMX) leadership • Q2 2025

    Question

    Asked about managing the grade 3 diarrhea rate for CX-2051, including alternative strategies beyond loperamide. Also inquired about the expected median follow-up in the Q1 update and plans for presenting at ASCO GI 2026.

    Answer

    Diarrhea is a key adverse event being managed. Prophylactic loperamide has been implemented, which was not used in the early part of the study. The company is focused on this strategy first. Regarding the Q1 update, they expect 'decent follow-up' on the majority of the ~70 patients but cannot provide a specific number. They are keeping all options open for the presentation venue and cannot comment on ASCO GI 2026 specifically.

    Ask Fintool Equity Research AI